CAS |
No.1071098-42-4 |
英文名称 |
AZA1 |
分子式 |
C22H20N6 |
分子量 |
368.43 |
溶解性 |
Soluble in DMSO |
纯度 |
≥98% |
外观(性状) |
Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
SMILES |
CC1=CC2=C(N1)C=CC(=C2)NC3=NC(=NC=C3)NC4=CC5=C(C=C4)NC(=C5)C |
InChIKey |
SYWHWWKOIJCMKF-UHFFFAOYSA-N |
InChI |
InChI=1S/C22H20N6/c1-13-9-15-11-17(3-5-19(15)24-13)26-21-7-8-23-22(28-21)27-18-4-6-20-16(12-18)10-14(2)25-20/h3-12,24-25H,1-2H3,(H2,23,26,27,28) |
PubChem CID |
25104141 |
靶点 |
Rac1;Cdc42 |
通路 |
Cell Cycle; GPCR & G Protein |
背景说明 |
是 Rac1 和 Cdc42 的有效抑制剂。 |
生物活性 |
AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1, an inhibitor of Ras homolog oncoprotein (Rho) GTPase family proteins, RAS-related C3 botulinus toxin substrate 1 (Rac 1) and Cell division control protein 42 homolog (Cdc42) markedly inhibited cell invasion of galectin-1 and galectin-3 suggesting that Rac 1 and Cdc42 may be involved in the regulation of H-ALCL cell invasion of galectins[1-2]. |
In Vitro |
In androgen-independent prostate Cancer cells, AZA1 inhibited both Rac1 and Cdc42 but not RhoA GTPase activity in a dose-dependent manner and blocked cellular migration and proliferation. Cyclin D1 expression significantly decreased following Rac1/Cdc42 inhibition in prostate Cancer cells. AZA1 treatment also down-regulated PAK and Akt activity in prostate Cancer cells, associated with induction of the pro-apoptotic function of BAD by suppression of serine-112 phosphorylation.[1] |
In Vivo |
Daily systemic administration of AZA1 for 2 weeks reduced growth of human 22Rv1 prostate tumor xenografts in mice and improved the survival of tumor-bearing Animals significantly.[1] |
细胞实验 |
AZA1 (Rac1/Cdc42-IN-1) (2-10 μM; 72 hours) blocks the proliferation of human prostate cancer cells 22Rv1 prostate cancer cells. AZA1 (2-10 μM; 24 hours) reduces phosphorylation of PAK1, AKT and BAD in EGF-stimulated 22Rv1 prostate cancer cells. AZA1 (10 μM; 24 hours) blocks Rac1 and Cdc42-dependent cell cycle events in 22Rv1 prostate cancer cells[1]. |
动物实验 |
AZA1 (Rac1/Cdc42-IN-1) (100 μg; i.p.; daily for 2 weeks) is potent in suppressing human 22Rv1 xenograft growth in mice and improving survival[1]. |
数据来源文献 |
[1]. Zins K, et al. A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. PLoS One. 2013;8(9):e74924. Published 2013 Sep 11. [2]. Suzuki O, et al. Sialylation and glycosylation modulate cell adhesion and invasion to extracellular matrix in human malignant lymphoma: Dependency on integrin and the Rho GTPase family. Int J Oncol. 2015;47(6):2091‐2099. |
规格 |
1mg 5mg 10mg |
单位 |
瓶 |